Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10404500 | 0.89 | MAPT (0.38) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10540280 | 0.89 | POLB (0.39) | HSD17B10POLBGAAL3MBTL1SMN1; SMN2 | |
| SCHEMBL8626971 | 0.89 | POLB (0.38) | MAPTPOLBGAAL3MBTL1SMN1; SMN2 | |
| SCHEMBL10543451 | 0.88 | SMN1; SMN2 (0.34) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL8622217 | 0.87 | POLB (0.35) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9329034 | 0.87 | POLB (0.33) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10547877 | 0.87 | KMT2A (0.40) | MAPTTHRBHSD17B10POLBGAA | |
| SCHEMBL10543923 | 0.87 | UGCG (0.39) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10762794 | 0.86 | POLB (0.33) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL10543031 | 0.86 | UGCG (0.31) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444237-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | Pfaendler, Hans Rudolf (DE) | 2004-08-11 | — | — | EP | claimed |
| WO-2003042219-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | PFAENDLER HANS RUDOLF (DE) | 2003-05-22 | — | — | WO | claimed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | claimed |
| US-20040260084-A1 | Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics | PFAENDLER HANS R (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1444237-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | Pfaendler, Hans Rudolf (DE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003042219-A1 | NOVEL C-3 S/O- AND S/N FORMALDEHE ACETAL DERIVATIVES OF CEPHALO SPORINS AND THEIR USE AS ANTIBIOTICS | PFAENDLER HANS RUDOLF (DE) | 2003-05-22 | — | — | WO | disclosed |
| EP-0503597-B1 | Penam derivatives and processes for producing the same | OTSUKA KAGAKU KK (JP) | 1998-06-10 | — | — | EP | disclosed |
| US-5599925-A | BACTERICIDES | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5389626-A | 3-aryloxmethyl-cephalosporin derivatives, and their medical use | SANKYO COMPANY, LIMITED (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0280240-B1 | Cephalosporin derivatives, process for their preparation and antibacterial agents | BANYU PHARMA CO LTD (JP) | 1994-09-14 | — | — | EP | disclosed |
| EP-0225634-B1 | Antibacterial compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-04-06 | — | — | EP | disclosed |
| EP-0160252-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-11-06 | — | — | EP | disclosed |
| US-4550105-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
| EP-0053815-B1 | 2-OXOAZETIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1985-05-08 | — | — | EP | disclosed |
| EP-0095764-A2 | 2-Oxoazetidinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-12-07 | — | — | EP | disclosed |
| EP-0083039-A1 | 4-Cyano-2-azetidinones and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1983-07-06 | — | — | EP | disclosed |
| EP-0053815-A1 | 2-Oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| EP-0050965-A1 | Beta-lactamase inhibitory composition | Takeda Chemical Industries, Ltd. (JP) | 1982-05-05 | — | — | EP | disclosed |
| EP-0021676-A1 | 3-Methoxy-2-oxoazetidine derivatives and their production | Takeda Chemical Industries, Ltd. (JP) | 1981-01-07 | — | — | EP | disclosed |
| EP-0021678-A1 | 1-Sulpho-2-oxoazetidine derivatives, their production and pharmaceutical compositions thereof | Takeda Chemical Industries, Ltd. (JP) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260084-A1 | Novel c-3 s/o-and s/n formaldehe acetal derivatives of cephalosporins and their use as antibotics | CBR3, CBR1, SULT1E1 | MAPT 4819/4885PDE3A 1036/4885SLC22A6 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.